Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus adjuvant chemoradiotherapy versus placebo plus adjuvant chemoradiotherapy after esophageal cancer surgery
ChiCTR2000039654Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- Dec 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of camrelizumab in esophageal cancer (2 arms), sponsored by The First Affiliated Hospital of Guangxi Medical University. Primary endpoints: Progression-free survival, Disease-free survival and 1 more. Started Dec 2020; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on ChiCTR2000039654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039654.